Compare · GCTK vs MDLN
GCTK vs MDLN
Side-by-side comparison of GlucoTrack Inc. (GCTK) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GCTK and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.40B, about 13161.2x GCTK ($3.4M).
- Over the past year, GCTK is down 93.9% and MDLN is down 17.1% - MDLN leads by 76.8 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 1 for GCTK).
- MDLN has more recent analyst coverage (25 ratings vs 0 for GCTK).
PerformanceGCTK-88.50%MDLN-17.07%
2025-12-17+0.00%2026-06-08
- Company
- GlucoTrack Inc.
- Medline Inc.
- Price
- $0.55-9.85%
- $33.80+0.58%
- Market cap
- $3.4M
- $44.40B
- 1M return
- -37.25%
- -19.55%
- 1Y return
- -93.90%
- -17.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 1
- 20
- Recent ratings
- 0
- 25
GCTK
GlucoTrack Inc.
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
Latest GCTK
- Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions
- GlucoTrack Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- SEC Form 10-Q filed by GlucoTrack Inc.
- GlucoTrack Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- GlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
- SEC Form EFFECT filed by GlucoTrack Inc.
- GlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)